Skip to main content
. Author manuscript; available in PMC: 2022 Nov 26.
Published in final edited form as: Semin Immunol. 2021 Nov 26;56:101537. doi: 10.1016/j.smim.2021.101537

Figure 1: In vivo cell reprogramming platforms are built for widescale adoption and expanded patient access.

Figure 1:

Listed are key advantages of in vivo cell reprogramming platforms based on injectable nanomedicines compared to conventional ex vivo engineered cell therapies.